

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **POLL RESULTS OF SPECIAL GENERAL MEETING**

The Board is pleased to announce that the ordinary resolutions as set out in the SGM Notice dated 23 December 2021 were duly passed at the SGM held on 8 February 2022.

### **RESULTS OF THE EGM**

References are made to the notice of special general meeting (the “**SGM Notice**”) and the circular (the “**Circular**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”), both dated 23 December 2021. Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context herein requires otherwise.

The board of directors (the “**Board**”) is pleased to announce that the ordinary resolutions as set out in the SGM Notice were duly passed by way of poll at the special general meeting (the “**SGM**”) held on 8 February 2022.

As at the date of the SGM, the Company had 1,894,500,000 Shares in issue including 697,500,000 Domestic Shares and 1,197,000,000 H Shares. Prior to the date of the SGM, Shareholders holding 1,726,784,500 Shares, representing approximately 91.15% of the total number of the Shares in issue as at the date of the SGM, had notified to the Company that they will attend the SGM either in person or by proxy. The actual number of the Shares attending the SGM either in person or by proxy was 662,500,000, representing approximately 34.97% of the total number of the Shares in issue as at the date of the SGM. The holding of the SGM shall comply with the Company Law of the PRC and the Articles of Association.

No Shareholder was required to abstain from voting in respect of the resolutions at the SGM. As such, there was a total of 1,894,500,000 Shares entitling the Shareholders to attend and vote on the resolutions at the SGM.

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the SGM as set out in Rule 17.47A of the GEM Listing Rules. No Shareholder has stated in his/her intention to vote against or to abstain from voting on any resolutions at the SGM.

Details of the poll results in respect of the resolutions proposed at the SGM were as follows:

Ordinary Resolutions		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
1.	To appoint Fan, Chan & Co. Limited as the auditor of the Company to fill the casual vacancy following the resignation of BDO Limited and to hold office until the conclusion of the next annual general meeting and to authorise the board of directors of the Company to fix their remuneration.	662,500,000 shares 100%	0 shares 0%	662,500,000 shares
2.	To appoint Mr. Zhao Zhiyou as the independent supervisor of the Company for a term commencing from the date of passing this resolution and ending upon the conclusion of the seventh session of the Supervisory Committee; to authorise the directors of the Company to negotiate the relevant remuneration and terms and conditions and to enter into a service contract with Mr. Zhao Zhiyou on behalf of the Company in accordance with the Articles of Association of the Company, the relevant laws of the People's Republic of China and the GEM Listing Rules of The Stock Exchange of Hong Kong Limited.	480,000,000 shares 72.45%	182,500,000 shares 27.55%	662,500,000 shares

*Note:* The percentages of votes are calculated based on the total number of the Shares held by the Shareholders who voted at the SGM either in person or by corporate representative or proxy.

As more than half of the votes present at the SGM either in person or by proxy had voted in favour of the above ordinary resolutions numbered 1 and 2, the above resolutions were duly passed as ordinary resolutions.

Ms. Sun Li, Mr. Hao Zhihui and Mr. He Xin as the executive Directors, Ms. Li Xueying as the non-executive Director and Mr. Li Xudong, Ms. Gao Chun and Mr. Wang Yongkang as the independent non-executive Directors attended the SGM.

Peking Certified Public Accountants, the Company's external accountant was appointed as the scrutineer of the SGM for the vote-taking.

By order of the Board  
**Tianjin TEDA Biomedical Engineering Company Limited**  
**Sun Li**  
*Chairman*

Tianjin, the PRC  
8 February 2022

*As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and He Xin; the non-executive Directors of the Company are Cao Aixin, Li Ximing and Li Xueying; the independent non-executive Directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.*

*This announcement, for which the Directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make this announcement or any statement herein misleading.*

*This announcement will remain on the “Latest Listed Company Information” page on the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven days from the date of its posting. This announcement will also be published and remain on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*